Sign In
Buy SRRA
$54.99
+0 (+0%)
At Close: Oct 03, 2022
Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis
08:06am, Friday, 06'th Aug 2021
Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent bindin
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial
07:00am, Monday, 21'st Jun 2021
—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical comp
Sierra Oncology: Time To Enter For The Big Pie
04:09pm, Wednesday, 27'th Jan 2021
For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier
